Poor
Mostly Not Aligned
Patient Risk:
Low
Summary
Only one core clinical concept is partially supported by the provided FDA label (adjunct to diet to reduce TG in severe hypertriglyceridemia). Most other claims (branding/availability, manufacturer, generic existence/equivalence, pricing/discount programs, and patent expiration) are not supported by the supplied label content.
Category Scores
Accurate Statements
VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
1 INDICATIONS AND USAGE: “as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.”
VASCEPA 4 grams per day reduced median TG (and other lipid parameters) from baseline relative to placebo in severe hypertriglyceridemia.
14.2 Severe Hypertriglyceridemia: “VASCEPA 4 grams per day reduced median TG, VLDL-C, and Apo B levels from baseline relative to placebo.”
Unsupported Statements
Vascepa is a prescription medication used to treat high triglycerides.
Partially supported only in the specific labeled context (adjunct to diet; severe TG ≥ 500 mg/dL in adults). The claim is too general and omits key labeled qualifiers.
Vascepa is available in the United States under the brand name Vascepa.
No such statement is provided/supported in the supplied label text.
Vascepa is manufactured by Amarin Corporation.
No manufacturer attribution is present/supported in the supplied label text.
Vascepa is a highly effective treatment option for patients with severe hypertriglyceridemia.
The label describes reductions in TG/lipid parameters, but “highly effective” is subjective and not an on-label efficacy phrase or anchored endpoint statement in the provided label excerpts.
Generic versions of brand-name medications are manufactured by other companies after the patent has expired.
Patent expiration and manufacturing timing are not part of the supplied FDA label content.
Vascepa generics are available online and in local pharmacies.
Retail/distribution channel availability and “generics” are not addressed in the supplied label text.
GoodRx is an online pharmacy that offers Vascepa generics at a lower cost than the brand-name medication.
Third-party pharmacy pricing/availability is not FDA label content in the supplied excerpts.
Rite Aid is a popular online pharmacy that offers Vascepa generics at a lower cost than the brand-name medication.
Third-party pharmacy pricing/availability is not FDA label content in the supplied excerpts.
RxAssist is a discount card program that offers discounts on prescription medications, including Vascepa generics.
Discount program claims are not FDA label content in the supplied excerpts.
NeedyMeds is a discount card program that offers discounts on prescription medications, including Vascepa generics.
Discount program claims are not FDA label content in the supplied excerpts.
Amarin Corporation offers a patient assistance program that can help eligible patients access Vascepa at a lower cost.
Patient assistance program claims are not FDA label content in the supplied excerpts.
Vascepa is a brand-name medication.
No explicit label support was provided in the supplied excerpts.
Generic versions of Vascepa are available.
The supplied FDA label excerpts do not address generic availability.
Vascepa generics are just as effective as the brand-name medication.
The supplied FDA label excerpts do not discuss generic vs brand equivalence/effectiveness.
Vascepa generics can be found online at pharmacies like GoodRx and Rite Aid or in local pharmacies.
Retail/distribution channel availability is not FDA label content in the supplied excerpts.
DrugPatentWatch.com provides information on patent expiration dates for various medications, including Vascepa.
Third-party website content is not part of FDA labeling.
According to DrugPatentWatch.com, the patent for Vascepa expired in 2020, making it possible for generic versions to be developed.
Patent expiration and generic-development timelines are not included in the supplied FDA label excerpts.
Contradictions
Important Omissions
For the asserted triglyceride treatment indication, the label specifies two distinct labeled uses (adjunct to maximally tolerated statin therapy to reduce risk in specific adult populations; and adjunct to diet to reduce TG in severe ≥500 mg/dL hypertriglyceridemia) and includes a limitation of use regarding pancreatitis risk not determined. These qualifiers were omitted in the general claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most mismatches are informational (e.g., availability/discount/patent/generic market claims) rather than direct dosing or safety instructions. The only clinically relevant claim is generalized and omits key labeled qualifiers (adult severe TG ≥500 mg/dL; adjunct to diet).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Large majority of claims are not supported by the provided FDA label excerpts (particularly generics, pricing/discount programs, and patent expiration).
Suggested Improvement
Restrict claims to the provided labeled indications and label-described outcomes (e.g., adjunct to diet for severe hypertriglyceridemia; adjunct to maximally tolerated statin for CV risk reduction in specified populations) and avoid third-party/patent/price/equivalence/generic availability statements that are not present in the supplied label.